Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE
Response to consultation

DATE
2019-02-20

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE: Response to consultation
DATE: 2018-12-04
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE
Response to consultation

DATE
2018-10-02

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

**POLICY TYPE**  
Response to consultation

**DATE**  
2018-09-06

**TOPICS**  
Health care and patient safety  
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE  Response to consultation
DATE  2018-08-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE Response to consultation
DATE 2018-07-18
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA response:

HEALTH CANADA CONSULTATION
ON RESTRICTION OF MARKETING
AND ADVERTISING OF OPIOIDS

Jun 14, 2018
Consultation on proposed front-of-package labelling

https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear (Recipient's Name),

The Canadian Medical Association (CMA) has taken the opportunity to participate in Health Canada's consultation on proposed front-of-package labelling of cannabis products. The CMA submits this response to inform the consultation of the critical role that physicians play in ensuring the responsible use of cannabis, and to provide the opportunity to respond to the restrictions on front-of-package labelling of cannabis products from a medical perspective.

Consumerlabelling for cannabis products is an area of high concern to the medical community. As the leading advocate for the health and well-being of Canadians, the CMA is concerned with the impact of cannabis labelling on the public's ability to make informed decisions about their health.

This letter highlights the concerns raised by the CMA in its previous submissions to Health Canada, including the need for clear and understandable labelling on cannabis products. The CMA is concerned that the proposed front-of-package labelling may not adequately address the need for clear and understandable information on the health risks and benefits of cannabis products.

The CMA recommends that the consultation reflect on the need to ensure that any front-of-package labelling is consistent with public health objectives and ensures that the public can make informed decisions about their health.

Sincerely,

[Signature]

Non-Medical Use of Cannabis Policy Team

CMA

[Date]
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE        2018-01-19
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE: Response to consultation
DATE: 2017-12-07
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE
Response to consultation

DATE
2017-11-7

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would restrict all products containing codeine to be sold by prescriber only.

November 7, 2017
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE  2017-06-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE  Response to consultation
DATE  2017-04-05
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE       2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
        Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE Response to consultation
DATE 2016-08-29
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Chief Stateman - Application d’Étapes

Introduction. This CMA’s submission to the Task Force on Marijuana Legalization and Regulation is based on the recommendation for the following principles and considerations:

1. Public health and safety
2. Truth and transparency
3. Fairness and justice
4. Economic
5. Cultural

As the CMA is the recognized leader in the field of medical cannabis, the following recommendations are based on the best available evidence and the conclusions of the Committee.

The CMA recommends that all Canadians, in their capacity as patients, be made aware of the potential risks associated with cannabis use, particularly in terms of addiction, respiratory health, and the impact on fetal development.

The CMA supports the implementation of plain and standardized packaging for cannabis products, as well as measures to reduce the appeal of cannabis to youth and prevent its sale to minors. The CMA also recommends the establishment of a robust monitoring system for the sale and use of cannabis to assess the impact of legalization.

The CMA recommends that the federal government consider the establishment of a national framework for cannabis regulation, including the development of a comprehensive cannabis education program.

For further information: cmanews@cma.ca

CMA Policybase - Canadian Medical Association p. 15
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE  Response to consultation
DATE        2016-08-12
TOPICS      Health care and patient safety
            Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE
Response to consultation

DATE
2016-03-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2016-01-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs Health care and patient safety</td>
</tr>
</tbody>
</table>

**Documents**
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE  Response to consultation
DATE  2015-06-08
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
<table>
<thead>
<tr>
<th><strong>POLICY TYPE</strong></th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DATE</strong></td>
<td>2014-08-26</td>
</tr>
</tbody>
</table>
| **TOPICS**     | Health care and patient safety  
Pharmaceuticals, prescribing, cannabis, drugs |

Documents